Education
About Us
Working with TipRanks
Follow Us
Precigen (PGEN)
NASDAQ:PGEN
PGEN Stock Chart & Stats
$3.74
-$0.11(-8.33%)
At close: 4:00 PM EST
$3.74
-$0.11(-8.33%)
Day’s Range― - ―
52-Week Range$0.65 - $5.23
Previous CloseN/A
Volume729.99K
Average Volume (3M)4.89M
Market Cap
$1.32B
Enterprise Value$987.65M
Total Cash (Recent Filing)$121.14M
Total Debt (Recent Filing)$98.19M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Mar 09, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding353,824,500
10 Day Avg. Volume5,907,804
30 Day Avg. Volume4,890,965
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)7.79
Price to Sales (P/S)76.40
P/FCF Ratio-3.91
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue156.55
Enterprise Value/Gross Profit681.14
Enterprise Value/Ebitda-4.04
Forecast
1Y Price Target
$9.00Price Target Upside140.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$12.31M
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company entered a $125M credit facility and received $100M, with cash and cash equivalents reported at approximately $121.1M, sufficient for foreseeable operations.
Market ExpansionA Marketing Authorization Application was filed with the EMA, and the company plans to find a commercial partner for a European launch, which could provide another growth opportunity.
New Drug ApprovalPapzimeos received full FDA approval as a therapy for the treatment of adults with recurrent respiratory papillomatosis, which was better than expected and announced earlier than the PDUFA action date.
Bears Say
Precigen News
PGEN FAQ
What was Precigen’s price range in the past 12 months?
Precigen lowest stock price was $0.65 and its highest was $5.22 in the past 12 months.
What is Precigen’s market cap?
Precigen’s market cap is $1.32B.
When is Precigen’s upcoming earnings report date?
Precigen’s upcoming earnings report date is Mar 09, 2026 which is in 101 days.
How were Precigen’s earnings last quarter?
Precigen released its earnings results on Nov 13, 2025. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$0.094 by -$0.966.
Is Precigen overvalued?
According to Wall Street analysts Precigen’s price is currently Undervalued.
Does Precigen pay dividends?
Precigen does not currently pay dividends.
What is Precigen’s EPS estimate?
Precigen’s EPS estimate is -0.08.
How many shares outstanding does Precigen have?
Precigen has 353,824,500 shares outstanding.
What happened to Precigen’s price movement after its last earnings report?
Precigen reported an EPS of -$1.06 in its last earnings report, missing expectations of -$0.094. Following the earnings report the stock price went up 25.648%.
Which hedge fund is a major shareholder of Precigen?
Currently, no hedge funds are holding shares in PGEN
Precigen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (140.64% Upside)
$9.00 (140.64% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $37.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
335.38%
12-Months-Change
Fundamentals
Return on Equity
-507.72%
Trailing 12-Months
Asset Growth
105.17%
Trailing 12-Months
Company Description
Precigen
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
PGEN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was optimistic, highlighting the transformative approval and rapid deployment of Papcemias, along with strong financial positioning and manufacturing capabilities. Despite increased expenses, the company anticipates reaching cash flow breakeven by 2026.View all PGEN earnings summariesPGEN Stock 12 Month Forecast
Average Price Target
$9.00
▲(140.64% Upside)
Technical Analysis
MiMedx Group
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Immunome
―
Praxis Precision Medicines
―
Ownership Overview
38.60% Insiders
10.82% Mutual Funds
16.08% Other Institutional Investors
29.47% Public Companies and
Individual Investors